TG Therapeutics Shares Are Trading Higher After the Company Announced It Updated Its Data Presentations to Include New Five-year Data From the ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) at the 2024 European Committee for...

Benzinga · Sep 18 21:13

TG Therapeutics Shares Are Trading Higher After the Company Announced It Updated Its Data Presentations to Include New Five-year Data From the ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

TG Therapeutics Shares Are Trading Higher After the Company Announced It Updated Its Data Presentations to Include New Five-year Data From the ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) at the 2024 European Committee for...

Risk Disclaimer